|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
19 February 2015 |
|
Main ID: |
NCT00583271 |
|
Date of registration:
|
20/12/2007 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
A Prospective Study of EUS Guided Celiac Block
|
|
Scientific title:
|
A Prospective Study of Endoscopic Ultrasound-guided Celiac (CB) Effectiveness |
|
Date of first enrolment:
|
June 2002 |
|
Target sample size:
|
127 |
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT00583271 |
|
Study type:
|
Observational |
|
Study design:
|
Observational Model: Cohort, Time Perspective: Prospective
|
|
Phase:
|
N/A
|
|
|
Countries of recruitment
|
|
United States
| | | | | | | |
|
Contacts
|
|
Name:
|
Julia LeBlanc, MD, MPH |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Indiana University |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Patients with chronic abdominal pain from documented chronic pancreatitis or
pancreatic cancer or other visceral malignancy that are undergoing EUS-guided CB (for
purposes other than this study) will be eligible to participate in this study.
- Patients with chronic pancreatitis and pancreatic cancer must have documented disease
by CT, ERCP, or EUS.
- No evidence of dementia or altered mental status that would prohibit the giving and
understanding of informed consent, and no evidence of psychiatric risk that would
preclude adequate compliance with this protocol.
- Patient must provide signed written informed consent
Exclusion Criteria:
- Patients that have had a previous celiac plexus block are eligible for this study
Age minimum:
18 Years
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Chronic Pancreatitis
|
|
Pancreatic Cancer
|
|
Intervention(s)
|
|
Drug: 98% dehydrated alcohol
|
|
Drug: triamcinolone
|
|
Secondary ID(s)
|
|
0205-04B
|
|
IRB #0205-04B
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|